Simvastatin induces neuroprotection in 6-OHDA-Lesioned PC12 via the PI3K/AKT/Caspase 3 pathway and anti-inflammatory responses

CNS Neuroscience and Therapeutics

Volumn 19, Issue 3, 2013, Pages 170-177

  Xu, Yun Qi ^a   Long, Ling ^a   Yan, Jun Qiang ^a,b   Wei, Lei ^a   Pan, Meng Qiu ^a   Gao, Hui Min ^a   Zhou, Peng ^a   Liu, Mei ^a   Zhu, Can Sheng ^a   Tang, Bei Sha ^c   Wang, Qing ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Apoptosis; Inflammation; Neurodegeneration; Neuroprotection; PI3K Akt; Simvastatin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 3; CYCLOOXYGENASE 2; DOPAMINE TRANSPORTER; INTERLEUKIN 6; OXIDOPAMINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PC12 CELL; RAT; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CASPASE 3; CYCLOOXYGENASE 2; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-6; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PC12 CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; RATS; SIGNAL TRANSDUCTION; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874383220     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12053     Document Type: Article

References (52)

1. Dolga AM, Nijholt IM, Ostroveanu A, Ten Bosch Q, Luiten PG, Eisel UL. Lovastatin induces neuroprotection through tumor necrosis factor receptor 2 signaling pathways. J Alzheimers Dis 2008;13:111-122.
2. Sugawara T, Ayer R, Jadhav V, Chen W, Tsubokawa T, Zhang JH. Simvastatin attenuation of cerebral vasospasm after subarachnoid hemorrhage in rats via increased phosphorylation of Akt and endothelial nitric oxide synthase. J Neurosci Res 2008;86:3635-3643.
3. Wang Q, Yan J, Chen X, et al. Statins: Multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol 2011;230:27-34.
4. Yan J, Xu Y, Zhu C, et al. Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: The association with anti-inflammatory responses. PLoS ONE 2011;6:e20945.
5. Arboleda G, Morales LC, Benítez B, Arboleda H. Regulation of ceramide-induced neuronal death: Cell metabolism meets neurodegeneration. Brain Res Rev 2009;59:333-346.
6. Seaborn T, Masmoudi-Kouli O, Fournier A, Vaudry H, Vaudry D. Protective effects of pituitary adenylate cyclase-activating polypeptide (PACAP) against apoptosis. Curr Pharm Des 2011;17:204-214.
7. Krafft PR, Altay O, Rolland WB, et al. α7 nicotinic acetylcholine receptor agonism confers neuroprotection through GSK-3β inhibition in a mouse model of intracerebral hemorrhage. Stroke 2012;43:844-850.
8. Mendelev N, Witherspoon S, Li PA. Overexpression of human selenoprotein H in neuronal cells ameliorates ultraviolet irradiation-induced damage by modulating cell signaling pathways. Exp Neurol 2009;220:328-334.
9. Vazquez de la Torre A, Junyent F, Folch J, et al. Study of the pathways involved in apoptosis induced by PI3K inhibition in cerebellar granule neurons. Neurochem Int 2011;59:159-167.
10. Dedoni S, Olianas MC, Onali P. Interferon-β induces apoptosis in human SH-SY5Y neuroblastoma cells through activation of JAK-STAT signaling and down-regulation of PI3K/Akt pathway. J Neurochem 2010;115:1421-1433.
11. Chan CB, Liu X, Pradoldej S, et al. Phosphoinositide 3-kinase enhancer regulates neuronal dendritogenesis and survival in neocortex. J Neurosci 2011;31:8083-8092.
12. Ahn JY, Rong R, Liu X, Ye Y. PIKE/nuclear PI 3-kinase signaling mediates the antiapoptotic actions of NGF in the nucleus. EMBO J 2004;23:3995-4006.
13. Wang G, Pan J, Chen SD. Kinases and kinase signaling pathways: Potential therapeutic targets in Parkinson's disease. Prog Neurobiol 2012;98:207-221.
14. Zhang S, Wang XJ, Tian LP, et al. CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease. J Neuroinflammation 2011;8:154.
15. Gui YX, Wang XY, Kang WY, et al. Extracellular signal-regulated kinase is involved in alpha-synuclein-induced mitochondrial dynamic disorders by regulating dynamin-like protein 1. Neurobiol Aging 2012;33:2841-2854.
16. Selley ML. Simvastatin prevents 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res 2005;1037:1-6.
17. Ghosh A, Roy A, Matras J, Brahmachari S, Gendelman HE, Pahan K. Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci 2009;29:13543-13556.
18. Rodriguez-Blanco J, Martín V, Herrera F, García-Santos G, Antolín I, Rodriguez C. Intracellular signaling pathways involved in post-mitotic dopaminergic PC12 cell death induced by 6-hydroxydopamine. J Neurochem 2008;107:127-140.
19. Park HH, Lee KY, Kim SH, Lee YJ, Koh SH. L-DOPA-induced neurotoxicity is reduced by the activation of the PI3K signaling pathway. Toxicology 2009;265:80-86.
20. Wasserman JK, Schlichter LC. Minocycline protects the blood-brain barrier and reduces edema following intracerebral hemorrhage in the rat. Exp Neurol 2007;207:227-237.
21. Naranjo-Suárez S, Castellanos MC, Alvarez-Tejado M, Vara A, Landázuri MO, del Peso L. Down-regulation of hypoxia-inducible factor-2 in PC12 cells by nerve growth factor stimulation. J Biol Chem 2003;278:31895-31901.
22. Iida J, Ishizaki H, Okamoto-Tanaka M, et al. Synaptic scaffolding molecule alpha is a scaffold to mediate N-methyl-d-aspartate receptor-dependent RhoA activation in dendrites. Mol Cell Biol 2007;27:4388-4405.
23. Bannon MJ, Poosch MS, Xia Y, Goebel DJ, Cassin B, Kapatos G. Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age. Proc Natl Acad Sci U S A 1992;89:7095-7099.
24. Afonso-Oramas D, Cruz-Muros I, Barroso-Chinea P, et al. The dopamine transporter is differentially regulated after dopaminergic lesion. Neurobiol Dis 2010;40:518-530.
25. Pan T, Zhu J, Hwu WJ, Jankovic J. The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells. PLoS ONE 2012;7:e45183.
26. Willey JZ, Elkind MS. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol 2010;67:1062-1067.
27. van der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL. Statins: Mechanisms of neuroprotection. Prog Neurobiol 2009;88:64-75.
28. Hernández-Romero MC, Argüelles S, Villarán RF, et al. Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide. J Neurochem 2008;105:445-459.
29. Jellinger KA. Interaction between α-synuclein and tau in Parkinson's disease comment on Wills et al.: Elevated tauopathy and α-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 2011;227:13-18.
30. Bezard E, Gross CE, Fournier MC, Dovero S, Bloch B, Jaber M. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp Neurol 1999;155:268-273.
31. Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 2003;184(Suppl 1):S68-S79.
32. Rong R, Ahn JY, Huang H, et al. PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis. Nat Neurosci 2003;6:1153-1161.
33. Chan CB, Chen Y, Liu X, et al. PIKE-mediated PI3-kinase activity is required for AMPA receptor surface expression. EMBO J 2011;30:4274-4286.
34. de Bartolomeis A, Fiore G, Iasevoli F. Dopamine-glutamate interaction and antipsychotics mechanism of action: Implication for new pharmacological strategies in psychosis. Curr Pharm Des 2005;11:3561-3594.
35. Pickel VM, Colago EE, Mania I, Molosh AI, Rainnie DG. Dopamine D1 receptors co-distribute with N-methyl-D- aspartic acid type-1 subunits and modulate synaptically-evoked N-methyl-D-aspartic acid currents in rat basolateral amygdala. Neuroscience 2006;142:671-690.
36. Wang Q, Zengin A, Deng C, et al. High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: The association with the up-regulation of NMDA receptor binding in the rat brain. Exp Neurol 2009;216:132-138.
37. Cerezo-Guisado MI, Garcia-Marin LJ, Lorenzo MJ, Bragado MJ. Lovastatin inhibits the growth and survival pathway of phosphoinositide 3-kinase/protein kinase B in immortalized rat brain neuroblasts. J Neurochem 2005;94:1277-1287.
38. Zhao TT, Trinh D, Addison CL, Dimitroulakos J. Lovastatin inhibits VEGFR and AKT activation: Synergistic cytotoxicity in combination with VEGFR inhibitors. PLoS ONE 2010;5:e12563.
39. Tsubaki M, Yamazoe Y, Yanae M, et al. Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-β as angiogenic factors in mouse osteosarcoma. Cytokine 2011;54:100-107.
40. Wu H, Lu D, Jiang H, et al. Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. J Neurotrauma 2008;25:130-139.
41. Sugawara T, Ayer R, Jadhav V, Chen W, Tsubokawa T, Zhang JH. Mechanisms of statin treatment in cerebral vasospasm. Acta Neurochir Suppl 2011;110(Pt 2):9-11.
42. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001;108:391-397.
43. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-1010.
44. Colin E, Régulier E, Perrin V, et al. Akt is altered in an animal model of Huntington's disease and in patients. Eur J Neurosci 2005;21:1478-1488.
45. van der Heide LP, Ramakers GM, Smidt MP. Insulin signaling in the central nervous system: Learning to survive. Prog Neurobiol 2006;79:205-221.
46. Sun ZK, Yang HQ, Pan J, et al. Protective effects of erythropoietin on tau phosphorylation induced by beta-amyloid. J Neurosci Res 2008;86:3018-3027.
47. Sugawara T, Jadhav V, Ayer R, Zhang J. Simvastatin attenuates cerebral vasospasm and improves outcomes by upregulation of PI3K/Akt pathway in a rat model of subarachnoid hemorrhage. Acta Neurochir Suppl 2008;102:391-394.
48. Liot G, Gabriel C, Cacquevel M, et al. Neurotrophin-3-induced PI-3 kinase/Akt signaling rescues cortical neurons from apoptosis. Exp Neurol 2004;187:38-46.
49. Takuma K, Baba A, Matsuda T. Astrocyte apoptosis: Implications for neuroprotection. Prog Neurobiol 2004;72:111-127.
50. Li Q, Ren J. Chronic alcohol consumption alters mammalian target of rapamycin (mTOR), reduces ribosomal p70s6 kinase and p4E-BP1 levels in mouse cerebral cortex. Exp Neurol 2007;204:840-844.
51. Signore AP, Weng Z, Hastings T, et al. Erythropoietin protects against 6-hydroxydopamine-induced dopaminergic cell death. J Neurochem 2006;96:428-443.
52. Fang CX, Yang X, Sreejayan N, Ren J. Acetaldehyde promotes rapamycin-dependent activation of p70(S6K) and glucose uptake despite inhibition of Akt and mTOR in dopaminergic SH-SY5Y human neuroblastoma cells. Exp Neurol 2007;203:196-204.